Cell Therapy for the degenerating intervertebral discs

退变椎间盘细胞疗法

基本信息

  • 批准号:
    7212018
  • 负责人:
  • 金额:
    $ 12.95万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-01-20 至 2010-12-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The trainee is a young physician with a strong basic science background. With the guidance of the rehabilitation scientist training program (RMSTP), she has designed a career path that brings together her scientific and clinical interests. Her research has attracted a considerable amount of positive attention in the field of rehabilitation. Seven full manuscripts resulted from this work: three have been published, one in press (see attached manuscript and letter), and three are in review. In addition, 15 abstracts have been presented at national and international meetings. The proposed research development plan will allow her to gain additional technical expertise under the guidance of seasoned scientists, and become an independent clinician-investigator. The trainee's research plan addresses an immensely important clinical problem, back pain. Although the etiology of back pain is most likely multi-factorial, intervertebral disc degeneration is perhaps causally associated with back pain. Biological treatment with a growth factor may promote matrix repair and restore physiological function. Cell-based gene therapy, which aims at the sustained release of growth factors, will be explored. This revised proposal contains new data further supporting the central hypothesis that cell therapy is likely to represent an effective tool for slowing or even reversing disc degeneration (1) Rabbit intervertebral disc (IVD) explants injected with allogenic rabbit articular chondrocytes transduced with Ad-hBMP-7 produce more hBMP-7 protein, and (2) Rabbit IVD explants injected with articular chondrocytes expressing hBMP-7 accumulate more proteoglycans. Based on these findings, the trainee proposes to study the effects of BMP-7 on degenerative rabbit intervertebral discs using the ex vivo gene transfer method. She has also performed a pilot in vivo study and transplanted allogenic rabbit articular chondrocytes into the degeneration rabbit IVD, demonstrating her ability to perform in vivo studies. Dr. Irving Shapiro, a disc biologist, has assumed the role of the trainee's primary mentor. Her in vivo study will also be helped by Dr. D. Greg Anderson, a spine surgeon, with extensive experience with the animal disc injury model. In the revised training plan, the trainee proposes to participate in course work and to learn additional techniques. Thomas Jefferson University provides a rich environment, and has a strong commitment to support her career development.
描述(由申请人提供):受训者是一名年轻的医生,具有很强的基础科学背景。在康复科学家培训计划(RMSTP)的指导下,她设计了一条职业道路,将她的科学和临床兴趣结合在一起。她的研究在康复领域引起了相当多的积极关注。七个完整的手稿产生了这项工作:三个已出版,一个在印刷(见所附手稿和信件),三个在审查。此外,在国家和国际会议上提交了15份摘要。拟议的研究开发计划将使她能够在经验丰富的科学家的指导下获得额外的技术专长,并成为一名独立的临床研究人员。 受训者的研究计划针对一个极其重要的临床问题,背痛。虽然背痛的病因很可能是多因素的,但椎间盘退变可能与背痛有因果关系。用生长因子进行生物处理可以促进基质修复和恢复生理功能。将探索以细胞为基础的基因治疗,其目的是持续释放生长因子。 该修订的提议包含进一步支持核心假设的新数据,即细胞疗法可能代表减缓或甚至逆转椎间盘退变的有效工具(1)用Ad-hBMP-7转导的同种异体兔关节软骨细胞注射的兔椎间盘(IVD)外植体产生更多的hBMP-7蛋白,(2)注射表达hBMP-7的关节软骨细胞的兔IVD外植体积累更多的蛋白多糖。基于这些发现,培训生提出使用离体基因转移方法研究BMP-7对退行性兔椎间盘的作用。她还进行了初步体内研究,并将同种异体兔关节软骨细胞移植到退化兔IVD中,证明了她进行体内研究的能力。 博士椎间盘生物学家欧文·夏皮罗(Irving Shapiro)担任了受训者的主要导师。她的体内研究也将得到D. Greg安德森,脊柱外科医生,具有丰富的动物椎间盘损伤模型经验。在修订后的培训计划中,受训人员提议参加课程工作并学习其他技术。托马斯杰斐逊大学提供了一个丰富的环境,并有一个强有力的承诺,以支持她的职业发展。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

YEJIA ZHANG其他文献

YEJIA ZHANG的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('YEJIA ZHANG', 18)}}的其他基金

Inhibition of TNF-alpha Signaling to Reduce Intervertebral Disc Inflammation
抑制 TNF-α 信号传导以减少椎间盘炎症
  • 批准号:
    10448429
  • 财政年份:
    2021
  • 资助金额:
    $ 12.95万
  • 项目类别:
Inhibition of TNF-alpha Signaling to Reduce Intervertebral Disc Inflammation
抑制 TNF-α 信号传导以减少椎间盘炎症
  • 批准号:
    10301274
  • 财政年份:
    2021
  • 资助金额:
    $ 12.95万
  • 项目类别:
Cell Therapy for the Degenerating Intervertebral Disc
退变椎间盘细胞疗法
  • 批准号:
    9032599
  • 财政年份:
    2015
  • 资助金额:
    $ 12.95万
  • 项目类别:
Cell Therapy for the degenerating intervertebral discs
退变椎间盘细胞疗法
  • 批准号:
    8010767
  • 财政年份:
    2010
  • 资助金额:
    $ 12.95万
  • 项目类别:
Cell Therapy for the degenerating intervertebral discs
退变椎间盘细胞疗法
  • 批准号:
    7687031
  • 财政年份:
    2007
  • 资助金额:
    $ 12.95万
  • 项目类别:
Cell Therapy for the degenerating intervertebral discs
退变椎间盘细胞疗法
  • 批准号:
    7752557
  • 财政年份:
    2007
  • 资助金额:
    $ 12.95万
  • 项目类别:
Cell Therapy for the degenerating intervertebral discs
退变椎间盘细胞疗法
  • 批准号:
    7342105
  • 财政年份:
    2007
  • 资助金额:
    $ 12.95万
  • 项目类别:
Cell Therapy for the degenerating intervertebral discs
退变椎间盘细胞疗法
  • 批准号:
    7544928
  • 财政年份:
    2007
  • 资助金额:
    $ 12.95万
  • 项目类别:

相似海外基金

cGAS-STING Pathway Targeting Replicative Adenoviruses with CD46 Tropism and AFP Promoter Conditional Replication Restriction for the Treatment of Hepatocellular Carcinoma
cGAS-STING 通路靶向具有 CD46 趋向性和 AFP 启动子的复制腺病毒条件性复制限制用于治疗肝细胞癌
  • 批准号:
    10436626
  • 财政年份:
    2021
  • 资助金额:
    $ 12.95万
  • 项目类别:
Glioma therapy with oncolytic adenoviruses and immunometabolic adjuvants
溶瘤腺病毒和免疫代谢佐剂治疗胶质瘤
  • 批准号:
    10557162
  • 财政年份:
    2021
  • 资助金额:
    $ 12.95万
  • 项目类别:
Molecular therapy of replication-competent adenoviruses targeting characteristic gene mutations found in mesothelioma
针对间皮瘤中发现的特征基因突变的具有复制能力的腺病毒的分子疗法
  • 批准号:
    21K08199
  • 财政年份:
    2021
  • 资助金额:
    $ 12.95万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Glioma therapy with oncolytic adenoviruses and immunometabolic adjuvants
溶瘤腺病毒和免疫代谢佐剂治疗胶质瘤
  • 批准号:
    10330464
  • 财政年份:
    2021
  • 资助金额:
    $ 12.95万
  • 项目类别:
Structural characterization of nucleoprotein cores of human adenoviruses
人腺病毒核蛋白核心的结构表征
  • 批准号:
    9807741
  • 财政年份:
    2019
  • 资助金额:
    $ 12.95万
  • 项目类别:
Molecular biology and pathogenesis of fowl adenoviruses
禽腺病毒的分子生物学和发病机制
  • 批准号:
    41625-2013
  • 财政年份:
    2018
  • 资助金额:
    $ 12.95万
  • 项目类别:
    Discovery Grants Program - Individual
The therapeutic strategies with augmented replications of oncolytic adenoviruses for malignant mesothelioma
溶瘤腺病毒增强复制治疗恶性间皮瘤的治疗策略
  • 批准号:
    18K15937
  • 财政年份:
    2018
  • 资助金额:
    $ 12.95万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Molecular biology and pathogenesis of fowl adenoviruses
禽腺病毒的分子生物学和发病机制
  • 批准号:
    41625-2013
  • 财政年份:
    2017
  • 资助金额:
    $ 12.95万
  • 项目类别:
    Discovery Grants Program - Individual
Research on detection of novel adenoviruses by genetic methods
新型腺病毒的基因检测研究
  • 批准号:
    16K09118
  • 财政年份:
    2016
  • 资助金额:
    $ 12.95万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Exploring the effects of nutrient deprivation on T cells and oncolytic adenoviruses, in order to create immune activators for tumour therapy
探索营养剥夺对 T 细胞和溶瘤腺病毒的影响,以创造用于肿瘤治疗的免疫激活剂
  • 批准号:
    1813152
  • 财政年份:
    2016
  • 资助金额:
    $ 12.95万
  • 项目类别:
    Studentship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了